ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 7:00AM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, today announced that Jaume Pons,
Ph.D., Founder, President and Chief Executive Officer and other
senior executives, will participate in a fireside chat at H.C.
Wainwright’s Global Life Sciences Conference, being held virtually
on March 9-10, 2021.
The prerecorded fireside chat will be available on Tuesday,
March 9, 2021 at 7:00 a.m. Eastern Time here and can be accessed by
visiting the Investors section of ALX Oncology’s website at
www.alxoncology.com and selecting Events under the News and Events
tab. A replay of the webcast will be archived for up to 30 days
following the presentation date.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage
immuno-oncology company focused on helping patients fight cancer by
developing therapies that block the CD47 checkpoint pathway and
bridge the innate and adaptive immune system. ALX Oncology’s lead
product candidate, ALX148, is a next generation CD47 blocking
therapeutic that combines a high-affinity CD47 binding domain with
an inactivated, proprietary Fc domain. ALX148 has demonstrated
promising clinical responses across a range of hematologic and
solid malignancies in combination with a number of leading
anti-cancer agents. ALX Oncology intends to continue clinical
development of ALX148 for the treatment of a range of solid tumor
indications as well as MDS and AML. For more information, please
visit ALX Oncology’s website at www.alxoncology.com.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212) 600-1902
alxoncology@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Mar 2024 to Apr 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Apr 2023 to Apr 2024